There is no known gene for any major psychiatric disorder, nor is one ever likely to be found, explained Stephan M. Stahl, MD, PhD, adjunct professor of psychiatry, University of California San Diego, during an overview of the age of personalized medicine and the role of pharmacogenetics at a session of the 2017 Neuroscience Education Institute Congress.
There is no known gene for any major psychiatric disorder, nor is one ever likely to be found, explained Stephen M. Stahl, MD, PhD, adjunct professor of psychiatry, University of California San Diego, during an overview of the age of personalized medicine and the role of pharmacogenetics at a session of the 2017 Neuroscience Education Institute Congress (NEI).
“The classical theory is that genes cause mental illness, but that theory does not work for psychiatry,” he said.
Genes do not code for psychiatric disorders or psychiatric symptoms, but what they do code for is proteins and epigenetic regulators, many of which regulate the efficiency of information processing in brain circuits, which can be visualized with neuroimaging techniques, explained Stahl, who is also chairman of NEI. Currently, psychiatry research is attempting to link circuits upstream to treatment response and downstream to regulatory genes.
The way an individual inherits a psychiatric disorder or responsiveness to one treatment over another is determined by a genotype having a subtle molecular abnormality, which causes abnormal information processing, which leads to behavior with complex functional interactions and emergent phenomena, said Stahl.
Psychiatric disorders, while descriptive and reliable, are not predictive of treatment response or linked to neurology and therefore are not diseases.
“Each psychiatric disorder is likely to represent many diseases, perhaps hundreds,” said Stahl.
The current diagnostic strategy is to attempt to link symptoms domains that cut across psychiatric disorders to inefficient information processing in specific brain circuits.
There are 4 different genotypes that affect drug metabolism:
Stahl finished up the session by discussing how genetic testing fits in modern psychiatric practice.
According to Stahl, pharmacogenomics can add to the modern psychiatric practice because they are:
For treatment-resistant patients, Stahl recommended providers:
“Genetic testing as a clinical tool is still in its infancy,” concluded Stahl. “Genotyping may be especially useful for patients who do not respond to or tolerate a drug as expected. Caution is essential when bringing genetic testing into the selection of treatment in clinical practice.”
The Importance of Examining and Preventing Atrial Fibrillation
August 29th 2023At this year’s American Society for Preventive Cardiology Congress on CVD Prevention, Emelia J. Benjamin, MD, ScM, delivered the Honorary Fellow Award Lecture, “The Imperative to Focus on the Prevention of Atrial Fibrillation,” as the recipient of this year’s Honorary Fellow of the American Society for Preventive Cardiology award.
Listen
Neurologists Share Tips for Securing Patient Access to Gene Therapies
March 19th 2025Tenacious efforts at every level, from the individual clinician to the hospital to the state to Congress, will be needed to make sure patients can access life-saving gene therapies for neuromuscular diseases.
Read More
Promoting Equity in Public Health: Policy, Investment, and Community Engagement Solutions
June 28th 2022On this episode of Managed Care Cast, we speak with Georges C. Benjamin, MD, executive director of the American Public Health Association, on the core takeaways of his keynote session at AHIP 2022 on public health policy and other solutions to promote equitable health and well-being.
Listen
EMBARK Data Show Continued Improvements With DMD Gene Therapy
March 19th 2025Data from the EMBARK trial of delandistrogene moxeparvovec in patients with Duchenne muscular dystrophy (DMD) show that benefits in functional outcomes, gene expression, and muscle imaging persist 2 years after receiving the gene therapy.
Read More
How Access to SMA Treatment Varies Globally and by Insurance Type
March 18th 2025Posters presented at the 2025 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference show that therapeutic advances in treating spinal muscular atrophy (SMA) are not uniformly making it into the hands of patients who could benefit.
Read More